tag:www.gov.uk,2005:/search/news-and-communications News and communications 2026-07-21T11:22:49+01:00 HM Government tag:www.gov.uk,2005:/government/news/mhra-approves-worlds-first-lower-carbon-beclometasone-inhalers-for-patients-with-asthma 2026-07-21T11:22:49+01:00 MHRA approves world's first lower-carbon beclometasone inhalers for patients with asthma The new inhalers use a next-generation propellant designed to reduce environmental impact while maintaining the same established treatment. tag:www.gov.uk,2005:/government/news/nerandomilast-jascayd-approved-to-treat-adult-patients-with-idiopathic-pulmonary-fibrosis-and-progressive-pulmonary-fibrosis 2026-07-08T11:15:48+01:00 Nerandomilast (Jascayd) approved to treat adult patients with Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis As with any medicinal product, the MHRA will keep the safety and effectiveness of nerandomilast under close review.   tag:www.gov.uk,2005:/government/news/mhra-approvesretifanlimabzynyz-for-the-treatment-of-advanced-merkel-cell-skin-cancer 2026-07-06T11:07:00+01:00 MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced Merkel cell skin cancer Merkel cell carcinoma (MCC) is a rare and aggressive type of skin cancer that develops from Merkel cells, specialised neuroendocrine cells found in the top layer of the skin.   tag:www.gov.uk,2005:/government/news/semaglutide-wegovy-approved-to-treat-form-of-liver-disease 2026-07-03T15:25:57+01:00 Semaglutide (Wegovy) approved to treat form of liver disease The semaglutide injection has been approved to treat metabolic-associated steatohepatitis (MASH) in adults with moderate-to-advanced liver fibrosis. tag:www.gov.uk,2005:/government/news/making-regulation-a-catalyst-not-a-barrier-for-uk-life-sciences 2026-07-02T14:54:37+01:00 Making regulation a catalyst, not a barrier, for UK life sciences MHRA CEO argues that for the UK’s long-term health and prosperity, regulation should help lead, rather than follow, innovation tag:www.gov.uk,2005:/government/news/mhra-authorises-gemcitabine-delivery-system-for-adults-with-bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer 2026-07-01T14:35:44+01:00 MHRA authorises gemcitabine delivery system for adults with BCG-unresponsive high-risk non-muscle invasive bladder cancer As with any medicinal product, the MHRA will keep the safety and effectiveness of the intravesical delivery system containing gemcitabine under close review.   tag:www.gov.uk,2005:/government/news/lower-dose-needle-free-allergy-treatment-approved-for-younger-children 2026-06-12T15:01:45+01:00 Lower dose needle-free allergy treatment approved for younger children As with any medicine, the MHRA will keep the safety and effectiveness of the adrenaline nasal spray under close review.   tag:www.gov.uk,2005:/government/news/first-glp-1-tablet-for-weight-loss-approved-in-the-uk 2026-06-11T16:03:39+01:00 First GLP-1 tablet for weight loss approved in the UK Having met the MHRA’s rigorous standards of safety, quality and effectiveness, the semaglutide tablet has been approved in the UK for weight loss and weight management. tag:www.gov.uk,2005:/government/news/nipocalimab-imaavy-authorised-to-treat-adults-and-adolescents-with-generalised-myasthenia-gravis 2026-06-09T13:26:23+01:00 Nipocalimab (Imaavy) authorised to treat adults and adolescents with generalised myasthenia gravis As with all medicines, the MHRA will keep the safety and effectiveness of Nipolcalimab under close review. tag:www.gov.uk,2005:/government/news/adjuvanted-trivalent-influenza-vaccineauthorised-for-adults-aged-50-and-over 2026-06-04T15:58:21+01:00 Adjuvanted trivalent influenza vaccine authorised for adults aged 50 and over The adjuvanted trivalent influenza vaccine works by stimulating the immune system to produce its own protection against flu. tag:www.gov.uk,2005:/government/news/resmetirom-rezdiffra-authorised-to-treat-metabolic-dysfunction-associated-steatohepatitis-mash-in-adults 2026-06-03T16:26:00+01:00 Resmetirom (Rezdiffra) authorised to treat metabolic dysfunction-associated steatohepatitis (MASH) in adults Resmetirom is used in adults who have experienced inflammation and cell damage, resulting in scarring. tag:www.gov.uk,2005:/government/news/rilzabrutinib-authorised-to-treat-adults-with-immune-thrombocytopenia-when-prior-treatments-have-been-insufficient 2026-05-29T12:29:08+01:00 Rilzabrutinib authorised to treat adults with immune thrombocytopenia when prior treatments have been insufficient  As with any medicine, the MHRA will keep the safety and effectiveness of rilzabrutinib under close review. tag:www.gov.uk,2005:/government/news/landmark-new-plans-bring-treatments-for-rare-diseases-a-step-closer 2026-05-21T00:01:00+01:00 Landmark new plans bring treatments for rare diseases a step closer The MHRA launches public consultation on new framework that could lead to earlier licensing for therapies for up to 3.5 million people in the UK. tag:www.gov.uk,2005:/government/news/mhra-approves-beremagene-geperpavec-vyjuvek-for-the-treatment-of-dystrophic-epidermolysis-bullosa 2026-05-15T19:09:20+01:00 MHRA approves beremagene geperpavec (Vyjuvek) for the treatment of dystrophic epidermolysis bullosa As with any medicine, the MHRA will keep the safety and effectiveness of Vyjuvek under close review. tag:www.gov.uk,2005:/government/news/mhra-approves-donidalorsen-dawnzera-for-the-treatment-of-hereditary-angioedema 2026-05-07T15:03:00+01:00 MHRA approves donidalorsen (Dawnzera) for the treatment of hereditary angioedema MHRA approves donidalorsen (Dawnzera) for the treatment of hereditary angioedema tag:www.gov.uk,2005:/government/news/mhra-approves-linerixibat-lynavoy-for-the-treatment-of-itch-due-to-biliary-tract-disease 2026-05-01T14:26:42+01:00 MHRA approves Linerixibat (Lynavoy) for the treatment of itch due to biliary tract disease As with all medicines, we will continue to closely monitor the safety and effectiveness of linerixibat as it is used more widely. tag:www.gov.uk,2005:/government/news/enflonsia-clesrovimab-cfor-approved-to-prevent-rsv-in-newborns-and-infants 2026-04-22T11:49:08+01:00 Enflonsia (clesrovimab-cfor) approved to prevent RSV in newborns and infants As with any medicine, the MHRA will keep the safety and effectiveness of Enflonsia under close review. tag:www.gov.uk,2005:/government/news/sevabertinib-approved-to-treat-adults-with-her2-positive-lung-cancer-that-has-spread-or-cannot-be-removed-by-surgery 2026-04-02T10:11:50+01:00 Sevabertinib approved to treat adults with HER2-positive lung cancer that has spread or cannot be removed by surgery  As with any medicine, the MHRA will keep the safety and effectiveness of sevabertinib under close review. tag:www.gov.uk,2005:/government/news/patients-to-get-new-medicines-up-to-six-months-sooner-under-new-joint-mhra-nice-approval-process 2026-03-17T16:05:06+00:00 Patients to get new medicines up to six months sooner under new joint MHRA-NICE approval process New pathway set to synchronise licensing and value assessment decisions tag:www.gov.uk,2005:/government/news/mhra-approves-deuruxolitinib-leqselvi-to-treat-severe-alopecia-areata-in-adults 2026-03-12T09:28:00+00:00 MHRA approves deuruxolitinib (Leqselvi) to treat severe alopecia areata in adults  As with any medicine, the MHRA will keep the safety and effectiveness of deuruxolitinib under close review.